M&A at Symantec
Software security company Symantec Corporation (NASDAQ:SYMC) is 1% higher in morning trading after announcing that it will acquire fellow security firm Blue Coat for $4.65 billion in cash. Blue Coat is a leader in web security, with a portfolio of integrated technologies serving more than 15,000 customers worldwide. It did around $755 million in revenue during the 12 months ended April 30 and was set to price its IPO before Symantec’s purchase. As part of the deal, current Blue Coat CEO Greg Clark will step up to the CEO seat at Symantec once the transaction closes, likely in the third quarter of this year. Symantec expects to realize $150 million in annual cost synergies and anticipates its EPS for fiscal year 2018 to be $1.70-to-$1.80 versus the consensus estimate of $1.39. Symantec Corporation (NASDAQ:SYMC) was in 33 hedge funds’ portfolios at the end of the first quarter among those that we monitor.
Pfizer’s Inotuzumab Ozogamicin Makes Progress
Pfizer Inc. (NYSE:PFE) is trending after a Phase 3 clinical trial showed that the company’s investigational drug inotuzumab ozogamicin demonstrated superiority versus chemotherapy in adult patients with refractory/relapsed CD22-positive acute lymphoblastic leukemia. Given that the survival rates for that particular type of leukemia are low, there will likely be great demand for the drug should the FDA approve it. Despite the news, shares of Pfizer Inc. (NYSE:PFE) are off by 0.45%, mainly due to broader market weakness. Ken Fisher‘s Fisher Asset Management was a top shareholder of Pfizer at the end of March.
BioScrip Hops on the M&A Bandwagon
BioScrip Inc (NASDAQ:BIOS) is 16% in the red this morning after acquiring HS Infusion Holdings for $80 million in cash and $5 million in stock. The acquisition also includes a contingent consideration of 3.1 million and 2.475 million restricted stock units which will vest when BioScrip’s 20-day average trading price exceeds $4.00 and $5.00 a share respectively, subject to certain time restrictions and circumstances. HS Infusion, which did $109 million in sales in 2015, is a provider of home nursing and home infusion products and services to patients suffering from both chronic and acute medical conditions. Bioscrip’s management expects to realize $14 million-to-$17 million in synergies within 12-to-18 months after the deal closing. BioScrip has also announced a public offering of common stock to finance the deal. BioScrip Inc (NASDAQ:BIOS) was in the portfolios of 13 funds in our database as of the most recent 13F reporting period.